跳至主要内容
临床试验/IRCT20201202049568N3
IRCT20201202049568N3招募中1 期

Evaluation of the Safety and Efficiency of human Umbilical Cord Derived Mesenchymal Stem Cell Exosomes in patients with ARDS of COVID-19; An interventional randomized double-blind controlled clinical trial: phase I and II

Tarmim Ava Baran Knowledge Based Company0 个研究点目标入组 72 人开始时间: 待定最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
发起方
入组人数
72

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 65 years(—)
性别
All

入选标准

  • Acute respiratory distress Syndrome of moderate to severe type (PaO2/ FiO2 <200mmHg)
  • Age range between 18 to 65 years
  • Men and Women
  • No participation in another clinical trial during this study
  • Patients who have given themselves and their families a full explanation of the study process and have obtained informed written consent
  • Chest X-ray showed bilateral infiltration with pulmonary edema
  • Definitive infection with COVID-19 confirmed by PCR

排除标准

  • Cancer or malignant diseases
  • Pregnant women or planning to become pregnant
  • Inflammatory diseases
  • Symptoms or history of liver or kidney failure
  • History of lung surgery or Lung transplantation
  • Having an autoimmune disease
  • Metabolic disorders (such as diabetes)
  • Infectious viral infection
  • Proven blood clotting disorders
  • Participate in other clinical trials simultaneously
  • Severe trauma occurred within 14 days before screening
  • They are undergoing hemodialysis or peritoneal dialysis
  • Bone marrow transplantation
  • Have a history of epilepsy, need continuous anticonvulsant therapy

研究者

发起方
Tarmim Ava Baran Knowledge Based Company

相似试验